Pilot Study Dara-CyBorD in Newly Diagnosed Multiple Myeloma Patients With Renal Failure

Active:	Yes
Cancer Type:	Kidney Cancer Multiple Myeloma	NCT ID:	NCT06142396
Trial Phases:	Phase I	Protocol IDs:	54767414MMY2095 (primary)
Eligibility:	, Male and Female	Study Type:
Study Sponsor:	Augusta University
NCI Full Details:	https://clinicaltrials.gov/study/NCT06142396

Summary

The goal of this study is to assess the efficacy of induction treatment with daratumumab-hyaluronidase (dara SC) with cyclophosphamide, bortezomib, and dexamethasone (Dara-CyBorD) for four cycles in patients with newly diagnosed multiple myeloma who have new onset renal failure. This study will also investigate the difference responses in African American (AA) patients versus non-African American patients.

Objectives

The primary questions this study aims to answer are:

To evaluate the very good partial response rate (VGPR) after 4 cycles of Dara-CyBord.
To evaluate the renal response rate (RRR) after 4 cycles of Dara-CyBord.

Treatment Sites in Georgia

Georgia Cancer Center at Augusta University
1411 Laney Walker Boulevard
Augusta, GA 30912
www.augusta.edu/cancer/

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.